Objective. Observational data suggest that hyperuricemia and gout are associated with increased mortality, while allopurinol use is associated with reduced mortality. In addition, the protective effect of allopurinol may be dose dependent. The aim of the current study was to determine whether allopurinol dose escalation is associated with cause-specific mortality in patients with gout.
Allopurinol dosing strategies are critical for optimizing gout care but may limit our understanding of the effects of dose variation on mortality risk. Current guidelines recommend that patients be started on a low dose of allopurinol, ≤100 mg daily, followed by slow titration to higher doses (13) . While randomized controlled trials (RCTs) of ULTs have used static dosing strategies (14) (15) (16) , such strategies are suboptimal and should now be considered unethical (17) . Future RCTs will likely require dose escalation until patients achieve the goal of lowering the serum urate (SU) level to <6.0 mg/dl. However, the desire for all patients to achieve this outcome, referred to as the SU goal, may impede researchers' ability to understand whether ULT dose-escalation strategies would reduce the risk of mortality in gout. Further limitations to the development of an RCT evaluating whether appropriate ULT dose escalation favorably impacts mortality are the large sample sizes and lengthy duration of follow-up that would be required to achieve sufficient statistical power.
Observational studies of comparative effectiveness are an important complement to RCTs, especially for the prediction of long-term outcomes such as mortality (18) . It has been shown that a substantial portion of primary care providers, who are responsible for~95% of gout management, use a static ULT dosing strategy for gout patients (19) . However, a small but meaningful number of providers use an early dose-escalation strategy, consistent with the current guidelines (13) , thus providing an opportunity for comparison. Using a national population of gout patients, we investigated the effect of ULT dose escalation on mortality. Specifically, we hypothesized that patients whose allopurinol dose was escalated (dose escalators) would experience a lower incidence of cause-specific cardiovascular-and cancer-related mortality as compared to similarly matched gout patients whose allopurinol dose was not escalated (non-escalators) over a 2-year period.
PATIENTS AND METHODS
Study setting. We studied gout patients receiving care from the US Department of Veterans Affairs (VA) Health Administration (VHA) from 1999 to 2010. The VHA has provided care for between 5 and 10 million retired US military enrollees each year since 2001. Data from the VHA electronic medical and pharmacy records represent information on the longitudinal care provided to veterans at 152 medical centers and 1,400 additional community-based outpatient clinics nationwide. These data, including demographic characteristics, outpatient and inpatient visits, laboratory results, and pharmacy dispensing records, were accessed from the VHA Corporate Data Warehouse (CDW) through the VA Informatics and Computing Infrastructure (20) . All pharmacy dispensing dates and doses used in this study represent prescriptions that were filled for the patient. Studies have reported on the completeness and validity of various CDW data, including diagnosis codes for gout (21, 22) .
Study population. The study cohort was defined as any gout patient age ≥40 years who was initiated on allopurinol treatment (incident allopurinol prescription), which accounts for >90% of all first-line ULTs used for gout, between October 1, 2001 and December 31, 2008 . Gout was defined as having at least 1 International Classification of Diseases, Ninth Revision (ICD-9) code for gout (ICD-9 code 274.XX) prior to the incident allopurinol prescription, with a second ICD-9 code for gout separated by at least 30 days. Febuxostat, approved in February 2009, is now considered a first-line ULT (13), but was not available beyond RCT participants during the enrollment period. Patients were required to have a record of significant hyperuricemia, which was defined for this study as an SU level of ≥8.0 mg/dl, to reflect a population of gout patients most likely to need dose escalation. In addition, patients were required to have at least 1 year of observability without allopurinol use prior to the incident allopurinol dispense date (new users). Observability was defined as having at least 1 annual VHA primary care or rheumatology visit and filling at least 1 prescription every 6 months (23).
Patients were excluded if they had an estimated glomerular filtration rate (eGFR) of <30 ml/minute/1.73 m 2 (24) , were involved in a clinical trial for ULT during the observation period, or had a history of dialysis, organ transplantation, malignancy, allopurinol hypersensitivity, or tumor lysis syndrome (11, 12) . These exclusions were intended to limit the population of interest to patients for whom gout was the primary indication for allopurinol.
Mortality outcomes. The primary outcomes for this study were cause-specific cardiovascular-and cancer-related mortality as defined using the National Death Index (NDI). The NDI is a centralized database of death record information reflecting state vital statistics office records, is maintained by the US Centers for Disease Control and Prevention, and is matched to VHA data by the VHA Suicide Data Repository. The records include date of death and cause of death as recorded by ICD-10 codes. Cardiovascular-related mortality was defined as any mortality attributed to an ICD-10 code within Chapter IX (I00-I99), and cancer-related mortality was defined as an ICD-10 code within Chapter II (C00-D48). Competing risks for cardiovascular-and cancer-related mortality were other causes of mortality. Furthermore, cancer was a competing risk for cardiovascularrelated mortality, and vice versa.
ULT dose escalation. Dose escalation was defined over a 2-year period, which we estimated would encompass a majority of the dose escalation occurring as part of the initiation of allopurinol. Planned dose escalation early in treatment is broadly endorsed in international gout management guidelines, and 2 years appears to be enough time for an overwhelming majority of patients to begin a planned dose escalation (13) . Using data from a single VA Medical Center (25), we found that~70% of all allopurinol dose escalation occurred within 2 years of a new allopurinol prescription. As longer periods of time elapse from the point of allopurinol initiation, it becomes more likely that intervening events will have an impact on the decision to escalate dose.
Patients were identified as "dose escalators" if their final average daily dose within the 2-year period was greater than their initial average daily dose. Patients were allowed to switch to treatment with febuxostat, and the dose of febuxostat considered equivalent to that of allopurinol was estimated based on clinical trial data demonstrating that similar proportions of patients receiving a dose of 300 mg/day of allopurinol and those receiving a dose of 40 mg/day of febuxostat will reach the SU goal (42% versus 45%, respectively) (16) . For this analysis, we estimated that the 3 febuxostat doses observed during follow-up (40, 80 , and 120 mg/day) were approximately equivalent to 300, 600, and 900 mg/day of allopurinol, respectively. Thus, a patient switching from allopurinol 100 mg/day to febuxostat 40 mg/day was considered to be a dose escalator.
Within-prescription dose escalations were determined through review of select medication instructions by at least 2 reviewers (BWC and DAB). Patients having within-prescription dose escalations were categorized as dose escalators if their final average daily dose for their last fill during the dose-escalation period was greater than the initial dose from their first fill.
Propensity score matching. In order to mitigate confounding by indication, we used propensity score matching to balance baseline confounders and prognostic variables between dose escalators and non-escalators. Our methods build on prior work using a propensity matching approach for allopurinol initiation among patients with hyperuricemia (11) . For each patient, we calculated the predicted probability (propensity score) of receiving dose escalation over the 2-year dose-escalation period, using logistic regression. To address time trends in allopurinol use and confounders prior to matching, patients were sorted into 1-year accrual blocks from October 2001 to December 2008 (total of 7 blocks) based on the date of incident allopurinol prescription fill. Within each block, dose escalators and nonescalators were matched 1:1 using nearest neighbor matching, based on the logit of the propensity score. We used a caliper of 0.2 times the standard deviation of the logit to limit allowable differences (26) . We used a greedy match algorithm such that, after matching to a dose escalator, non-escalators were removed from the pool of potential matches (26) .
Variables used to develop propensity scores for the primary analysis, designated model 1, were assessed over a baseline period of up to 2 years prior to initial allopurinol receipt. Baseline characteristics included demographics ( ]), health care utilization, and gout-specific factors. Comorbidity was quantified using the Rheumatic Disease Comorbidity Index (27) .
The total number of primary care visits during the baseline period was used as a proxy for health care use. The number of outpatient gout diagnoses on record, presence of a rheumatology consult, presence of a baseline rheumatology prescriber of allopurinol, and presence of an inpatient gout diagnosis as the primary discharge diagnosis during the baseline period were used as proxies for gout burden. Finally, the patients' baseline SU concentration nearest to the incident allopurinol date and the index allopurinol dose were included as gout-specific factors.
A second model, designated model 2, was developed to start time-at-risk after a 2-year dose escalation period to assess the effect of changing patient characteristics and medication adherence over the dose-escalation period. Patient characteristics for model 2 were evaluated over the 2-year dose-escalation period, with the exception of baseline SU concentration and index allopurinol dose. Model 2 also included the proportion of days covered (PDC) to estimate medication adherence to allopurinol. PDC is the number of days the patient had medication available out of the total days of observation (days with medication available/days of observation) after adjusting for early refills and truncating at the end of observation. The Pharmacy Quality Alliance endorses the PDC as the preferred method for assessing medication adherence using pharmacy claims data (28) .
Statistical analysis. Baseline characteristics of eligible dose escalators and non-escalators were assessed using standardized differences (29) . Balance diagnostics were used to assess the mean values and distributions of baseline characteristics of the matched groups. Mean values for each matched group were compared using standardized differences (26) . Standardized differences of <0.1 were considered negligible (26) . Distributions of continuous variables were compared using variance ratios, quantile-quantile plots, and nonparametric density plots (30) . The plots were visually assessed for deviations in distributions between groups. Nonlinear and interaction terms were subsequently considered if the diagnostics indicated that there was an inadequate balance of baseline characteristics (30, 31) .
For model 1, time-at-risk for both groups began on the date of incident allopurinol prescription fill, but time prior to patients' first dose-escalation event among those in the dose escalation group was assigned as the time-at-risk for the non-escalator group. This approach significantly reduces the risk of immortal time bias impacting our estimates (32). Model 2 was developed to simultaneously address changes in patient characteristics over the dose-escalation period and immortal time bias, by using baseline characteristics assessed over the 2-year dose-escalation period and by beginning time-at-risk 2 years after the date of incident allopurinol prescription fill, when dose escalation had likely occurred. Both models are depicted in Supplementary To account for competing risks, both cause-specific and subdistribution (Fine-Gray) hazard models were constructed, consistent with published best practices (33, 34) . The cause-specific hazard model provides an estimate of the relative effect of dose escalation on the cause-specific mortality rate in patients who have not died from any cause, while the subdistribution model gives an estimate of the effect of dose escalation on the cause-specific mortality rate in patients who have not died from the cause of interest. The cause-specific hazard estimate (33) is often preferred to answer epidemiologic questions of etiology such as in the current study. We present cause-specific hazard model ratios (HRs) herein, while subdistribution hazard model estimates are provided in Supplementary Figures and Tables (http: //onlinelibrary.wiley. com/doi/10.1002/art.40486/abstract). Cumulative incidence plots, constructed using Fine-Gray subdistribution hazard models, depict the effect of dose escalation on cardiovascular-and cancer-related mortality in the presence of other causes of mortality. A Cox proportional hazards model was used to estimate the effect of dose escalation on all-cause mortality, with the 95% confidence intervals (95% CIs) being based on robust variance estimates to account for matching (31, 35) .
Propensity score matching may not effectively control for confounding if quality of care concurrent to ULT dose escalation is markedly different between dose escalators and non-escalators for common comorbidities. To assess this possibility, we examined baseline and 2-year follow-up values for 3 quality-of-care variables: percentage of patients with blood pressure readings of 1300 COBURN ET AL <140 mm Hg systolic or <90 mm Hg diastolic among those treated for hypertension (receiving beta-blockers, CCBs, thiazides, loop diuretics, ACE inhibitors, or ARBs), the percentage of patients with a glycosylated hemoglobin (hemoglobin A 1C ) level of <9% among those treated for diabetes (receiving insulin, metformin, or other oral agents for hypoglycemia), and the percentage of patients with a cholesterol level of <200 mg/dl among those treated for hyperlipidemia (receiving statins or fibrates).
We also report the percentage of patients with complete observability during the 2-year dose-escalation period, using the aforementioned definition applied to the pre-index period. Sensitivity analyses were conducted with adjustment for the 2-year dose-escalation period to assess patients' baseline characteristics beginning at the time of dose escalation (designated model 3, with results shown in Supplementary Figure 1 , http://onlinelibrary. wiley.com/doi/10.1002/art.40486/abstract), trimming the top and bottom 2.5 percentile of the propensity distribution, limiting the cohort to those achieving the SU goal of <6.0 mg/dl, and excluding patients who switched to febuxostat. All analyses were conducted in SAS Enterprise Guide version 7.1 (SAS Institute).
RESULTS
Characteristics of the study groups. A total of 31,335 patients met the eligibility criteria for the study, and of those, 25,378 had complete data required for propensity score matching (Figure 1 ). Prior to matching for model 1, the 7,336 dose escalators were similar to the 18,042 non-escalators with regard to a majority of the baseline characteristics (Table 1) . Only health care utilization measures, BMI, colchicine and prednisone use, and the SU level exceeded a standardized difference of 0.1, indicating a potentially important imbalance between the dose escalator and non-escalator groups. Those receiving dose escalation had a slightly higher baseline SU level (mean 9.7 mg/dl versus 9.4 mg/dl), higher BMI (32.6 kg/m 2 versus 31.9 kg/m 2 ), greater use of colchicine (62% versus 54%) and prednisone (27% versus 20%), and lower incident allopurinol dose (median 100 mg/day versus 200 mg/day), and were more likely to have a rheumatologist involved in their care (18% versus 7% for a rheumatologist prescribing the initial allopurinol; 24% versus 12% for a rheumatology clinic visit during baseline). Switching to febuxostat was rare, occurring in 30 dose escalators and 2 non-escalators.
In model 2, characteristics that had been similar in both groups at baseline differed between the groups at year 2 (Table 1 and Supplementary Figure 2 , http://onlinelibrary. wiley.com/doi/10.1002/art.40486/abstract). In addition, dose escalators had greater medication adherence than nonescalators during the 2-year escalation period (median PDC 0.83 versus 0.70).
The dates of incident allopurinol prescription in model 1 were well distributed over time, with the number of eligible dose escalators and non-escalators during each accrual block ranging from 798 to 1,399 and from 2,148 to 2,914, respectively. After propensity score matching, all baseline characteristics were balanced (standardized differences ≤0.04) ( Table 1) . Consistent with the demographic characteristics of a typical VA gout population (36), the mean age was 64 years and >99% of patients were male. The majority of patients had comorbid hypertension, cardiovascular disease, or diabetes, and use of medications for these conditions was common. The propensity scorematched groups had similar rheumatology contact, with 11-12% having their initial allopurinol prescribed by a rheumatologist and 17-18% having visited a rheumatology clinic. Similar distributions across accrual blocks and balancing of baseline characteristics were observed in model 2 (Supplementary Table 1 A total of 111,694 patients met the inclusion criteria, and then 80,359 patients were excluded based on the presence of at least 1 exclusion criterion. Baseline variables were defined for 31,335 eligible patients. Complete data were required for analysis, leaving a final cohort of 25,378 patients for propensity matching. Of these patients, 12,856 (51%) were matched using 1:1 nearest neighbor propensity score matching. The exclusions for the serum urate (SU) level and estimated glomerular filtration rate (eGFR) included patients who were missing 2-year baseline data (n = 42,914 and n = 25,427, respectively). VHA = US Department of Veterans Affairs Health Administration; BMI = body mass index.
Among dose escalators over the 2-year follow-up period in model 1, the average daily dose of allopurinol was increased by a median of 100 mg/day and 90% of increases were between 50 mg/day and 300 mg/day. Only 10% of patients in the dose-escalation group escalated to a final dose of >300 mg/day (Table 2) .
Dose escalators were more likely than non-escalators to achieve the SU goal during the follow-up period (31% versus 12%) ( Table 3) . Similar results were observed in model 2 (data not shown).
Mortality. In model 1, there were 2,867 deaths during the observation period, with 1,384 occurring in the dose escalator group and 1,483 in the non-escalator group (Supplementary Table 2 , http://onlinelibrary.wiley. com/doi/10.1002/art.40486/abstract). The mean followup was 5.6 years for dose escalators and 5.5 years for non-escalators (P = 0.04), resulting in mortality rates of 42.5 per 1,000 person-years among dose escalators and 38.7 per 1,000 person-years among non-escalators. There was an 8% increase in the all-cause mortality rate among dose * Except where indicated otherwise, values are the percent of patients. BMI = body mass index; RDCI = Rheumatic Disease Comorbidity Index; IQR = interquartile range; ACE = angiotensin-converting enzyme; ARBs = angiotensin II receptor blockers; CCBs = calcium channel blockers; NSAIDs = nonsteroidal antiinflammatory drugs; eGFR = estimated glomerular filtration rate (based on the Modification of Diet in Renal Disease equation). † Standardized difference (Std. diff.) ≥0.1 (values <0.1 were considered negligible). The standardized difference is the preferred statistic for between-group comparisons in propensity studies, because the statistic is independent of sample size and thus provides a consistent measure before and after matching (30) . ‡ Race was categorized as white, non white, or unknown due to refusal to answer or due to being unknown by the patient, which is consistent with Department of Veterans Affairs self-report of race data standards. The "race unknown" category is considered missing in the standardized difference calculation, while all other calculations include "race unknown" as a category.
escalators compared to non-escalators (HR 1.08, 95% CI 1.01-1.17) (Figure 2A ). With regard to cardiovascular-related deaths, there were 644 among dose escalators and 694 among non-escalators, leading to cardiovascular mortality rates of 19.8 and 18.1 per 1,000 person-years, respectively. With regard to cancer-related deaths, there were 223 among dose escalators and 240 among non-escalators, translating to cancer mortality rates of 6.8 and 6.3 per 1,000 personyears, respectively. Allopurinol dose escalation was not associated with a statistically significant difference in cardiovascular-related mortality (HR 1.08, 95% CI 0.97-1.21) ( Figure 2B ) or cancer-related mortality (HR 1.06, 95% CI 0.88-1.27) (Figure 2C ), although the effect sizes were similar to those observed for all-cause mortality. Similar HRs were obtained in the subdistribution hazard models (Supplementary Table 3 , http://onlinelibrary.wiley.c om/doi/10.1002/art.40486/abstract).
In model 2, the mortality incidence rates were similar to those observed in model 1 (results available in * Totals may add to more than 100% due to rounding. † Dose represents the average daily dose. Allopurinol equivalent doses were used for febuxostat in follow-up calculations. ‡ In a small proportion of non-escalators the dose was decreased during the 2-year follow-up (4%) or was escalated and then deescalated before the end of follow-up (6%). Figure 2 . Time to death in propensity-matched dose escalators compared to non-escalators. The cumulative incidence of all-cause mortality (A), cardiovascular-related mortality (B), and cancer-related mortality (C) during follow-up was calculated. Cumulative incidence plots were estimated using Fine-Gray subdistribution hazard models.
Supplementary Sensitivity analyses. In model 1, there were no differences in the proportion of patients whose blood pressure was <140/<90 mm Hg or whose hemoglobin A 1c level was <9% at baseline compared to 2 years' follow-up among those treated for hypertension or those treated for diabetes, respectively (Table 4) . At baseline, cholesterol control was similar in dose escalators and non-escalators. By the end of follow-up, slightly more dose escalators than non-escalators had achieved the goal of cholesterol control (81% versus 78%; P = 0.05), but the standardized difference remained <0.1. More dose escalators than non-escalators were prescribed colchicine (60% versus 48%; standardized difference 0.23) and oral prednisone (25% versus 18%; standardized difference 0.17) during follow-up.
In sensitivity analyses, we limited the cohort to the 2,000 dose escalators achieving the SU goal of <6.0 mg/dl at the end of the 2-year follow-up and their matched non-escalators. There was a 7% reduction in the risk of cardiovascular-related mortality with allopurinol dose escalation leading to achievement of the SU goal (HR 0.93, 95% CI 0.76-1.14), although this did not reach statistical significance. However, no effect on all-cause mortality or cancer-related mortality was observed (data not shown).
Broadening the criteria to any patient achieving the SU goal and their matched non-escalators, 2,527 individuals were retained for each group, with 767 nonescalators (37%) and 1,981 dose escalators (81%) achieving the SU goal. No trend toward effect was observed for cardiovascular-related, cancer-related, or all-cause mortality (data not shown). Baseline characteristics for both sensitivity analyses are available in Supplementary Table 5 (http://onlinelibrary.wiley.com/doi/10.1002/art.40486/abstract). Adjustment for changes in baseline patient characteristics prior to dose escalation (model 3) did not significantly affect the HR estimates (see Supplementary Tables 6  and 7 , http://onlinelibrary.wiley.com/doi/10.1002/art.40486/ abstract). Other sensitivity analyses had negligible effects on the estimates (data not shown).
DISCUSSION
In this study, there was no compelling evidence to suggest that allopurinol dose escalation is associated with meaningful reductions in mortality risk among patients with gout. Understanding the impact of allopurinol dose escalation on long-term outcomes such as mortality is timely in the wake of recent concerns over ULT use and cardiovascular risk. In November 2017, the US Food and Drug Administration issued a safety announcement based on findings from a recent RCT in which it was demonstrated that gout patients initiating treatment with febuxostat had a higher risk of cardiovascular-related mortality and all-cause mortality than did allopurinol initiators (37) . However, the RCT did not address the effect of dose escalation on mortality. In our study, there was a small (albeit statistically significant) increase in all-cause mortality among allopurinol dose escalators compared to nonescalators, and the effect size estimates were similar for cardiovascular-and cancer-related mortality, neither of which achieved statistical significance. These primarily null findings were demonstrated despite this being the largest study to date of ULT treatment effects on mortality among patients with gout (11, 12, 38) . We further demonstrated that patients receiving ULT dose escalation were only rarely escalated to levels typically required for proper gout control (13, 39) . Such "clinical inertia" limited our ability to examine the effect of optimal dose escalation on mortality (40) . This appears to be particularly relevant since gout patients receiving dose escalation and achieving the SU goal appeared to have a lower incidence of cardiovascular-related mortality in sensitivity analyses. Taken together, these results add to the persistent uncertainty regarding the role of ULTs in reducing mortality risk (6, 41) .
This study has a number of design strengths that further inform our understanding of ULT use and mortality risk. First, we successfully linked longitudinal data from a large national cohort of gout patients to vital status data, * Values are the percent of patients. BP = blood pressure; hemoglobin A 1C = glycosylated hemoglobin; PDC = proportion of days covered; NA = not applicable. † Observability at baseline was defined for a 1-year period, but was defined for the full 2-year dose-escalation period for follow-up. Patients were considered observable for the period if they were observable for both 1-year periods of follow-up. All laboratory values are the last on record during the 2-year follow-up if more than 1 was available. ‡ Standardized difference of ≥0.1 for comparison within the time period.
allowing for examination of cause-specific mortality. Previous studies have typically reported all-cause mortality rates only, thus limiting the understanding about the relative impact of therapy on different causes of mortality such as cardiovascular disease or cancer (11, 12) . Other studies have focused on the potential cardiovascular benefits of ULTs (41), but there is at least a theoretical potential that ULTs could impact cancer-related mortality (6, 42) . This effort, to our knowledge, is the first epidemiologic study to examine the association of allopurinol use with cancerrelated mortality.
We utilized a new-user, active-comparator design in this study, which is novel among studies of ULT treatment associations with mortality. This approach is particularly robust as it better reflects treatment decisions for both gout and hyperuricemia than would study designs that use comparisons against non-initiator groups (patients never treated with allopurinol). Designs in which patients with hyperuricemia initiated on therapy are compared to non-initiators likely reflect a comparison against a heterogeneous referent group with both low-and highrisk patients (43) . Specifically, the non-initiator group likely contains a high-risk population of patients whose illness is likely substantial or who may even be potentially near death, for whom prescribers are less likely to initiate a new medication (43) . Studies in other diseases have termed this the "risk-treatment mismatch" or "risk-treatment paradox" (44, 45) . The active-comparator design mitigates potential treatment allocation bias by comparing 2 groups initiating ULT, groups that were quite similar in this study even before propensity matching was undertaken.
Herein and in other studies, we have demonstrated that clinical inertia, or the lack of increasing treatment intensity when indicated (40) , is common in gout management, even among those receiving initial dose escalation (19) . It is possible that the clinical inertia observed in this study limited our ability to determine the effect of ULT dose escalation on mortality risk reduction. The potential that such under-dosing limited our findings is consistent with at least 1 study in which forearm blood flow, a measure of endothelial function, was found to be significantly increased in patients randomized to receive 600 mg/day allopurinol as compared to those who were assigned to receive allopurinol at a dose of 300 mg/day or to receive placebo (10). In the current study, only 10% of dose escalators ever achieved daily allopurinol doses exceeding 300 mg, and daily doses of ≥600 mg were rarely used (in only 4% of patients). It is also possible that allopurinol exerts a protective effect that is independent of the resulting SU concentrations. It has been suggested, for example, that allopurinol exerts a cardioprotective effect by acting as a xanthine oxidase inhibitor (7, 10, 41) , a mechanism for which dose escalation may be less relevant.
In addition, if the reduction in mortality risk hypothesized to be attributable to ULT use is associated with reductions in cumulative systemic inflammation from gout attacks (46) , then the dosing practices reported in this study are unlikely to decrease such inflammation. International guidelines, supported by evidence-based studies, recognize that dose escalation until the SU level is below 6.0 mg/dl is typically required for long-term reduction in gout attacks (13, 47) . Our sensitivity analysis examining the importance of SU goal attainment leaves open the possibility that reaching the SU goal may be important in terms of survival benefit, but further study will be needed. Albeit not reaching statistical significance, the 7% reduction in the mortality estimate would require at least 4,411 patients per group to demonstrate an effect in a 10-year study. Thus, these results should be interpreted with caution, and further study is warranted.
In place of ULT dose escalation, we could have considered the effect of SU goal attainment or SU change on mortality risk, similar to that examined in a recent study (38) . That approach would have directly investigated one of the hypothesized causal links, SU concentration, between ULT use and mortality reduction (6, 41) . However, we chose to focus on dose escalation for a number of reasons. First, the approach frames the issue as an RCT would, by comparing the effect of treatment strategies. Second, investigating dose escalation more broadly reflects the many hypothesized mechanisms through which allopurinol (or an alternative ULT) may reduce mortality. Finally, there are major gaps in the availability of SU assessments in observational cohorts, creating a potentially insurmountable missing data problem. In other reports, the availability of follow-up SU values have ranged from 15% to 30% at 6 months to 50% at 4 years (48) . Such infrequent testing and likely baseline differences between those with follow-up SU testing versus those without would have rendered even the best imputation techniques inadequate.
Despite the many strengths of this study, interpretation must account for limitations. This study is observational in nature. While the new-user, active-comparator design and use of propensity matching likely mitigated potential confounding by measured and unmeasured risk factors, this novel approach does not eliminate the potential for residual unmeasured confounding. To specifically address gout severity as a residual unmeasured confounder, we included baseline SU level, rheumatologist care, and number of gout diagnosis codes on record as proxies for severity. While these methods represent methodologic improvements over past studies, data from medical records remain insufficient to fully characterize gout severity. Inherent to the 2-year dose-escalation period in model 2, selection bias may be present, as nonescalators had a slightly higher number of deaths during that period than did dose escalators, but this did not appear to substantially affect the HR estimates as compared to model 1. This study is limited to a VA population, which may affect the generalizability of our findings to populations not well-represented in the VA, such as women. However, the VA is likely the single largest provider of care for gout patients in the US, with demographics that reflect those most at risk for gout (e.g., older age, male, and high cardiovascular comorbidity burden).
In conclusion, we found no association between allopurinol dose escalation and improved survival in patients with gout. The findings were likely limited by the suboptimal ULT dosing that is often observed in clinical practice, even among dose escalators. While we had anticipated that the results from this study would add to the evidence supporting the notion that appropriate dose escalation yields meaningful "extraarticular" benefits for gout patients, clinical inertia in this population was so prevalent, even among those receiving dose escalation, that we were unable to make a definitive assessment. Trial designs or interventions in day-to-day practice that overcome clinical inertia in ULT dose escalation will be needed before we can fully evaluate the potentially beneficial effects of dose escalation on mortality.
